Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the study alliance leukemia
Carsten Müller‐Tidow(Heidelberg University), Norbert Schmitz(University Hospital Münster), Steffen Koschmieder(RWTH Aachen University), Christian Thiede(University Hospital Carl Gustav Carus), Matthias Stelljes(University Hospital Münster), Trude Butterfaß‐Bahloul(University Hospital Münster), Roland Repp(Klinikum Oldenburg), Gerhard Ehninger(University Hospital Carl Gustav Carus), Norbert Frickhofen(Helios Dr. Horst Schmidt Kliniken Wiesbaden), Utz Krug(Klinikum Leverkusen), Alexander Kiani(Bayreuth Medical Center), Wolfgang E. Berdel(University Hospital Münster), Björn Steffen(Goethe University Frankfurt), Christoph Röllig(University Hospital Carl Gustav Carus), Claudia D. Baldus(University Hospital Schleswig-Holstein), Maria Eveslage(Zimmer Biomet (Germany)), Albrecht Reichle(University Hospital Regensburg), Aristoteles Giagounidis(Marien Hospital Düsseldorf), Tim H. Brümmendorf(National University Cancer Institute, Singapore), Andreas Neubauer(RWTH Aachen University), Michael Kiehl(Klinikum Frankfurt Höchst), Ulrich Thiem(Universität Hamburg), Petra Tschanter(University of Münster), Hartmut Link(Medizinische Hochschule Hannover), Mathias Hänel(Klinikum Chemnitz), Katharina S. Götze(Ludwig-Maximilians-Universität München), Volker Kunzmann(University of Würzburg), Ulrich Kaiser(University of Applied Sciences Landshut), Rudolf Peceny(Klinikum Osnabrück), Anja Koschmieder(University of Münster), Stefan W. Krause(Universitätsklinikum Erlangen), Richard Noppeney(Essen University Hospital), Hubert Serve(Goethe University Frankfurt), Martin Kaufmann(Robert Bosch Hospital), Martin Görner(Klinikum Bielefeld), W. Herr(University of Regensburg), K. Schäfer-Eckart(Klinikum Arnsberg), Ralph Naumann(University of Siegen), Martin Dugas(University of Münster), R. Wagner(University Hospital Münster)
Cited by 49
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k